We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
Read MoreHide Full Article
Mersana (MRSN - Free Report) plunged 59% as it announced that the FDA has placed a partial clinical hold on the enrollment of new patients in two of its ongoing clinical studies — UP-NEXT and UPGRADE-A. These studies were evaluating the efficacy of Mersana's lead product candidate, upifitamab rilsodotin (UpRi), in platinum-sensitive ovarian cancer.
The FDA's decision to pause new patient enrollment in phase III UP-NEXT study and phase I UPGRADE-A study followed the company’s submission of an aggregate safety report that evaluated bleeding events in approximately 560 patients who received UpRi.
The report indicated that there was a higher number of serious bleeding events compared with the expected background rate of bleeding in platinum-resistant ovarian cancer. Although most instances of bleeding were categorized as low-grade, the report identified five fatal Grade 5 bleeding events among patients treated so far. The causes of these bleeding events are being investigated.
As part of the partial clinical hold, the FDA is expected to request a comprehensive assessment of the safety data associated with UpRi, including the bleeding events.
Mersana’s phase II UPLIFT study of UpRi for platinum-resistant ovarian cancer remains untouched. The study finished enrolling patients in October 2022. Patients who were already enrolled in the study can still receive UpRi. The company plans to secure the UPLIFT study information and share its results by early August 2023.
The company aims to work with the FDA and address any concerns to lift the partial clinical hold and resume patient enrollment in UP-NEXT and UPGRADE-A.
Shares of Mersana have plunged 33.6% year to date compared with the industry’s 7.1% decline.
Image Source: Zacks Investment Research
This partial clinical hold represents a temporary setback for Mersana and its efforts to advance the development of UpRi.
In February 2022, Mersana partnered with Janssen Biotech, a subsidiary of Johnson and Johnson (JNJ - Free Report) , in a research collaboration and license agreement. The agreement aims to develop and market new ADCs for three types of cancer. It will do so using MRSN’s expertise in ADCs and Janssen's antibodies.
As part of the agreement, Janssen made an initial payment of $40.0 million to Mersana. Janssen has the option to choose up to three targets for the treatments. It can also change each target once before a specific deadline.
Loss per share estimate for ADMA Biologics has narrowed from 19 cents to 9 cents for 2023 in the past 90 days. Shares of ADMA Biologics have risen 2.9% year to date.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
Loss per share estimate for Omega Therapeutics has narrowed from $2.51 to $2.05 for 2023 in the past 90 days. Shares of the company have rallied 39.2% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
Mersana (MRSN - Free Report) plunged 59% as it announced that the FDA has placed a partial clinical hold on the enrollment of new patients in two of its ongoing clinical studies — UP-NEXT and UPGRADE-A. These studies were evaluating the efficacy of Mersana's lead product candidate, upifitamab rilsodotin (UpRi), in platinum-sensitive ovarian cancer.
The FDA's decision to pause new patient enrollment in phase III UP-NEXT study and phase I UPGRADE-A study followed the company’s submission of an aggregate safety report that evaluated bleeding events in approximately 560 patients who received UpRi.
The report indicated that there was a higher number of serious bleeding events compared with the expected background rate of bleeding in platinum-resistant ovarian cancer. Although most instances of bleeding were categorized as low-grade, the report identified five fatal Grade 5 bleeding events among patients treated so far. The causes of these bleeding events are being investigated.
As part of the partial clinical hold, the FDA is expected to request a comprehensive assessment of the safety data associated with UpRi, including the bleeding events.
Mersana’s phase II UPLIFT study of UpRi for platinum-resistant ovarian cancer remains untouched. The study finished enrolling patients in October 2022. Patients who were already enrolled in the study can still receive UpRi. The company plans to secure the UPLIFT study information and share its results by early August 2023.
The company aims to work with the FDA and address any concerns to lift the partial clinical hold and resume patient enrollment in UP-NEXT and UPGRADE-A.
Shares of Mersana have plunged 33.6% year to date compared with the industry’s 7.1% decline.
Image Source: Zacks Investment Research
This partial clinical hold represents a temporary setback for Mersana and its efforts to advance the development of UpRi.
In February 2022, Mersana partnered with Janssen Biotech, a subsidiary of Johnson and Johnson (JNJ - Free Report) , in a research collaboration and license agreement. The agreement aims to develop and market new ADCs for three types of cancer. It will do so using MRSN’s expertise in ADCs and Janssen's antibodies.
As part of the agreement, Janssen made an initial payment of $40.0 million to Mersana. Janssen has the option to choose up to three targets for the treatments. It can also change each target once before a specific deadline.
Mersana Therapeutics, Inc. Price and Consensus
Mersana Therapeutics, Inc. price-consensus-chart | Mersana Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Mersana currently has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are ADMA Biologics, Inc. (ADMA - Free Report) and Omega Therapeutics , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimate for ADMA Biologics has narrowed from 19 cents to 9 cents for 2023 in the past 90 days. Shares of ADMA Biologics have risen 2.9% year to date.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
Loss per share estimate for Omega Therapeutics has narrowed from $2.51 to $2.05 for 2023 in the past 90 days. Shares of the company have rallied 39.2% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.